Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Kidney Week in Denver: Day 2
Kidney Week in Denver: Day 1
On Instagram: deceased donor kidney transplantation versus continued dialysis- target trial
Survival benefit of deceased donor kidney transplantation versus continued dialysis
A more visual summary of the target trial emulation and relevant context (just 7 images to look at!). Infographics by Anca Stefan and Cristina Popa
Dietary nitrate supplementation in CKD pregnancy
FIND-CKD trial on Instagram
FIND-CKD on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Andreea Manolea
Bonus: more on finerenone in proteinuric CKD universe- visuals by Cristina Popa
TRACK trial on Instagram
TRACK trial on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
MAJESTY trial on Instagram
MAJESTY trial on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
Finerenone across the proteinuric CKD spectrum
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates
NephJC Internship 2026-2027
Making an IMPACT on BP: Why pills alone won't win the war
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
NephJC Short: Bayesian leash: How a prior walked the Tigris across the finish line
Why-dralazine?! Population risk of drug induced vasculitis
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
